Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Over the past 10 years, Zimmer Biomet (ZBH) earnings per share (EPS) grew 29.8% a year, revenue grew 3.2% a year and free cash flow grew 8.0% a year, with an average return on invested capital (ROIC) of 3.5%. ZBH stock trades at $95.74, a P/E of 11.3, below its historical average of 51.2. Analysts' average 12-month price target is $104.14 (+8.8%).
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 2.4% | 2.2% | 3.7% | C- |
| EPS GrowthEPS | 29.8% | 129.5% | 6.9% | A- |
| Revenue GrowthRevenue | 3.2% | 6.1% | 8.6% | C+ |
| Cash Flow GrowthCash Flow | 8.0% | 6.2% | 28.5% | A- |
| ROICROIC | 3.5% | 4.7% | 5.5% | C |
Exhibit B Valuation Ledger
- Current EPS
- $8.48
- Historical Avg P/E
- 51.2
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $50.58 | $46.38 | $55.94 | $53.77 | $58.19 | $57.19 | $58.42 | $57.16 | $59.52 | $61.15 | $63.90 | $65.48 | |
| Basic EPSEPS | $0.26 | $1.47 | $8.84 | -$1.81 | $5.36 | -$0.65 | $1.87 | $1.10 | $4.91 | $4.45 | $3.56 | $8.48 | |
| RevenueRevenue | $5,997,800,000 | $7,668,400,000 | $7,803,300,000 | $7,932,900,000 | $7,982,200,000 | $6,127,500,000 | $6,827,300,000 | $6,939,900,000 | $7,394,200,000 | $7,678,600,000 | $8,231,500,000 | $8,508,900,000 | |
| Free Cash FlowCash Flow | $682,100,000 | $1,447,500,000 | $1,426,300,000 | $1,584,700,000 | $1,181,100,000 | $1,092,600,000 | $1,347,200,000 | $1,067,100,000 | $1,187,100,000 | $1,142,600,000 | $1,472,600,000 | $1,830,000,000 | |
| ROIC (%)ROIC | 1.7% | 2.5% | 3.3% | 0.2% | 5.0% | 0.0% | 3.6% | 2.6% | 6.3% | 5.7% | 5.5% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
42 firms rate it — 17 buy, 22 hold, 3 sell · Most recent Aug 2026
ZBH Stock FAQ
What is ZBH's stock price target?
The average 12-month analyst price target for ZBH is $104.14, with a range of $93.00 to $120.00. That is +8.8% from the current price of $95.74.
Do analysts rate ZBH a buy?
Opinion is mixed. Of 42 firms covering Zimmer Biomet, the ratings are 17 buy or strong buy, 22 hold and 3 sell or strong sell.
How fast is Zimmer Biomet growing?
Annual growth rates for ZBH. EPS: 29.8% over 10 years, 129.5% over 5 years, 6.9% over 1 year. Revenue: 3.2% over 10 years, 6.1% over 5 years, 8.6% over 1 year. Free cash flow: 8.0% over 10 years, 6.2% over 5 years, 28.5% over 1 year. Book value per share: 2.4% over 10 years, 2.2% over 5 years, 3.7% over 1 year.
What is ZBH's ROIC?
Zimmer Biomet's return on invested capital (ROIC) was 5.5% in fiscal 2025. Its 10-year average ROIC is 3.5%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is ZBH's P/E ratio?
ZBH's current P/E ratio is 11.3, compared with a historical average of 51.2. Trailing earnings per share are $8.48.
What is Zimmer Biomet's market cap and stock price?
ZBH last traded at $95.74 as of October 30, 2026. Its 52-week range is $79.12 to $103.70. Zimmer Biomet has a market cap of $18.26B.
Exhibit D Related Coverage
Similar Stocks
Data as of October 30, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.